Thyroidectomy for Graves' Disease or Amiodarone-induced Thyrotoxicosis

The goal of this observational study is to learn about the potential differences in morbidity of thyroidectomy (removal of the thyroid gland) depending on the preoperative hormonal status. The main question it aims to answer is: Do patients undergoing thyroidectomy for thyreotoxicosis (thyroid hyperfunction) due to Graves' disease or Amiodarone induced thyreotoxicosis have comparable complication rates depending on their thyroid metabolic status prior or during the procedure. The data from participants undergoing a thyroidectomy at one of the study sites will be prospectively registered in the EUROCRINE registry, including an add-on module for additional study specific routine data. The operation itself, the preoperative or postoperative treatments are not altered in any way.

NCT Number	NCT06963203
Lead Sponsor	Andrea Goldmann Collaborators: Spital Männedorf, Spital Limmattal Schlieren, Centre Hospitalier Universitaire Vaudois, Ospedale Regionale di Mendrisio, Cantonal Hospital of St. Gallen, Cantonal Hosptal, Baselland, St. Claraspital AG, University Hospital, Geneva, Insel Gruppe AG, University Hospital Bern, ASZ Aalst, University Hospital Virgen de las Nieves, University of Nancy, Hospital Costa del Sol, Evgenidion Hospital Athens, Greece
Conditions	Graves Disease, Amiodarone-Induced Thyrotoxicosis, Thyroidectomy
Enrollment	486 participants
Start Date	2025-07-01
Primary Completion	2027-06 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2025-07-02